Analyst: New study confirms that Eli Lilly's tirzepatide is a good product

Eli Lilly has published strong results for its study of the diabetes treatment tirzepatide, which took up the last piece of the puzzle needed for an FDA application, Sydbank analyst Søren Løntoft Hansen says.
Photo: Sydbank/PR
Photo: Sydbank/PR

On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading